Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | DRD1 | P21728 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD5 | P21918 | 1/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3725632 | 0.84 | SMN1; SMN2 (0.64) | CYP2D6TSHRSYKSMN1; SMN2POLB | |
| SCHEMBL30726450 | 0.83 | DRD1 (0.56) | CYP2D6TSHRSMN1; SMN2POLBDRD1 | |
| SCHEMBL1853220 | 0.83 | DRD1 (0.62) | CYP2D6TSHRSMN1; SMN2POLBDRD1 | |
| SCHEMBL25374902 | 0.81 | KDM4E (0.57) | CYP2D6TSHRSMN1; SMN2POLBDRD1 | |
| SCHEMBL1953267 | 0.81 | TSHR (0.56) | CYP2D6TSHRSMN1; SMN2POLBDRD1 | |
| SCHEMBL5319656 | 0.80 | KDM4E (0.70) | CYP2D6TSHRSYKSMN1; SMN2POLB | |
| SCHEMBL5235337 | 0.80 | DRD1 (0.52) | CYP2D6TSHRSMN1; SMN2POLBDRD1 | |
| SCHEMBL13744516 | 0.80 | SMN1; SMN2 (0.66) | CYP2D6TSHRSYKSMN1; SMN2POLB | |
| Ammonia Solution, Strong SCHEMBL4267670 | 0.79 | KDM4E (0.68) | CYP2D6TSHRSYKSMN1; SMN2POLB | |
| SCHEMBL3378946 | 0.78 | DRD1 (0.50) | CYP2D6TSHRSMN1; SMN2POLBDRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964592-B2 | 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | NOVARTIS AG (CH) | 2011-06-21 | — | — | US | disclosed |
| US-20060247241-A1 | 2,4-Di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | NOVARTIS AG (CH) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247241-A1 | 2,4-Di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | TYMS, UMPS, TYMP | CYP2D6 345/4885TSHR 4318/4885SYK 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.